Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Clinical trial NCT02072967 · COMPLETED

Trial details

NCT number: NCT02072967
Sponsor: Astellas Pharma Europe B.V.
Status: COMPLETED
Study type: OBSERVATIONAL

Lymphoma, Non-Hodgkin

Start date: 2012-05-01
Primary completion: 2015-10-01
Enrollment: 97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.